The BioWorld Insider Podcast
One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.
- Update frequency
- every 29 days
- Average duration
- 22 minutes
- Episodes
- 50
- Years Active
- 2021 - 2025
Merck’s new COVID-19 pill will save lives, but at what price?
Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., may have never had a chance to move out of the un…
Newly approved cervical cancer drug Tivdak gives patients a new option
The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the company's president and CEO, Jan van de Winkel.
…
DNA vaccines: a better path to taming the pandemic?
An in-depth conversation with Lucio Rovati, CEO and chief scientific officer of Italy’s Rottapharm Biotech as they tackle the new world of DNA vaccines.
Hosted on Acast. See acast.com/privacy for …
Rising to the COVID-19 challenge, clinical trials evolve
Laurie Halloran, president and CEO of Boston-based Halloran Consulting, shares her thoughts on the impact of COVID-19 on clinical trials.
A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on
Mark Goldsmith, Revolution Medicines Inc. president, CEO and chairman, talks about grappling with RAS mutations.
Hosted on Acast. See acast.com/privacy for more information.
As dementia cases grow, biomarkers and new therapies key to unlocking treatment
Howard Fillit, founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation, shares his insights on the impact of financial investments driving these therapies.
As biopharma deals keep pace, M&A volumes languish
Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers.
Hosted on Acas…
Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal
Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal.
Hosted on Acast. See acast.com/privacy for more information.
Finally, a new medicine for Alzheimer’s disease
Biogen’s vice president of global and U.S. medical affairs for Alzheimer’s disease offers insight into Aduhelm.
Hosted on Acast. See acast.com/privacy for more information.
